SCHEMBL1706141

SCHEMBL1706141

O=CCSC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 19/20 0.50
DNMT1 P26358 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19814065 0.85 KIF11 (0.61) KIF11
SCHEMBL1526445 0.79 KIF11 (0.57) KIF11
SCHEMBL1648406 0.78 KIF11 (0.50) KIF11
SCHEMBL28658067 0.75 KIF11 (0.54) KIF11DNMT1
SCHEMBL34230 0.74 KIF11 (0.50) KIF11
SCHEMBL20545942 0.74 PAM (0.46) KIF11DNMT1
Acetic Acid SCHEMBL329771 0.74 KIF11 (0.48) KIF11DNMT1
SCHEMBL18176011 0.71 KIF11 (0.52) KIF11
SCHEMBL19119641 0.71 KIF11 (0.44) KIF11
SCHEMBL974721 0.71 KIF11 (0.63) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561634-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF MediBoston Limited (HK) 2025-06-04 EP disclosed
CN-119894535-A Oritastatin derivatives and conjugates thereof 祐方有限公司 2025-04-25 CN disclosed
US-20240108744-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF FORTVITA BIOLOGICS LIMITED (CN) 2024-04-04 US disclosed
WO-2024023735-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF MEDIBOSTON LIMITED (CN) 2024-02-01 WO disclosed
CN-104324394-A Molecular probe developer, as well as preparation method and application thereof CHENGDU YAOHANG TECHNOLOGY CO LTD 2015-02-04 CN disclosed
US-8747810-B2 Compositions and methods for imaging tissues, organs and tumors PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-06-10 US disclosed
US-8747810-B2 Compositions and methods for imaging tissues, organs and tumors PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-06-10 US disclosed
US-20120269724-A1 COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-10-25 US disclosed
US-20120269724-A1 COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-10-25 US disclosed
US-8198218-B2 Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2012-06-12 US disclosed
EP-2440584-A1 COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS President and Fellows of Harvard College (US) 2012-04-18 EP disclosed
WO-2010144891-A1 COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-12-16 WO disclosed
WO-2010144891-A1 COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-12-16 WO disclosed
US-20100022499-A1 HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 2010-01-28 US disclosed
US-20090118140-A1 METHOD AND SYSTEM FOR ASSEMBLY OF MACROMOLECULES AND NANOSTRUCTURES XF TECHNOLOGIES INC. 2009-05-07 US disclosed
WO-2008112980-A2 METHOD AND SYSTEM FOR ASSEMBLY OF MACROMOLECULES AND NANOSTRUCTURES INCITOR, LLC (US) 2008-09-18 WO disclosed
US-20030207400-A1 Vectors for dna delivery BIANCHI ELISABETTA (IT) 2003-11-06 US disclosed
EP-0618221-A2 Heterocyclic inhibitors of farnesyl protein transferase BRISTOL-MYERS SQUIBB COMPANY (US) 1994-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269724-A1 COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS SSTR3, TACR1, SSTR5 KIF11 4726/4885DNMT1 3680/4885
US-20240108744-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF AURKA, AURKC, AURKB KIF11 227/4885DNMT1 1067/4885
US-20100022499-A1 HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS AADAC, ABCG2, RICTOR KIF11 3214/4885DNMT1 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.